Reference:
Pfizer. (2021). Comirnaty 30 micrograms/dose concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified) tozinameran: Package leaflet. Retrieved from [insert URL here]
Summary:
Comirnaty is a COVID-19 mRNA vaccine designed to prevent illness caused by the SARS-CoV-2 virus, approved for adults and adolescents aged 12 and over. It functions by stimulating the immune system to produce antibodies without containing the virus itself. The vaccine is administered in a two-dose regimen, with the second dose given three weeks after the first. There are precautions for individuals with severe allergies or compromised immune systems. Side effects are common, including pain at the injection site, fatigue, and headaches, with rare cases of myocarditis and pericarditis reported. Storage guidelines specify ultra-low temperatures for frozen vials, and the vaccine must be diluted before administration. Close contacts of recipients are also encouraged to be vaccinated. This leaflet stresses the importance of reporting side effects and provides guidance on storage, dosage, and usage to ensure optimal safety.